- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07599098
Effects of a Pilates Studio Program on Quality of Life and Functional Capacity of Women Undergoing Breast Cancer Treatment (Cancer)
Effects of a Pilates Studio Program on Quality of Life, Functional Capacity, Pain, Fatigue, Sarcopenia, Flexibility, Strength, Body Composition, Self-Esteem, Anxiety and Depression in Women Undergoing Breast Cancer Treatment
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Andréa D Reis Dra., Teacher
- Telefonnummer: 98987220570
- E-Mail: andrea.dr@ufma.br
Studieren Sie die Kontaktsicherung
- Name: Hyrllanny P Santos Hyrllanny Pereira dos Santos, Student
- Telefonnummer: 98988359435
- E-Mail: hyrllanny.santos@discente.ufma.br
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Women aged 18 or older;
- Being under treatment for breast cancer (chemotherapy, radiotherapy, immunotherapy and/or hormone therapy);
- No previous neurological/musculoskeletal disorders that impede active movement;
- No recent surgeries.
Exclusion Criteria:
- Patients with problems secondary to breast cancer that limit active movement;
- Presence of inflammation or edema in the abdomen, groin, and upper and lower extremities;
- Having another type of cancer;
- Having a cognitive impairment or injury that prevents them from performing physical assessments or completing questionnaires.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Pilates Studio Programming Group
The intervention will consist of 16 weeks of in-person Pilates studio classes, three times a week in the mornings, lasting 60 minutes each, totaling 48 sessions.
|
There will be 16 weeks of intervention, with in-person Pilates studio classes three times a week, lasting 60 minutes each, in the morning, totaling 48 sessions. The classes will follow this order: Warm-up with initial stretches, lasting 10 minutes. This will be followed by the Pilates program lasting 40 minutes, and concluding with a 10-minute relaxation period. Every four weeks there will be a progression in intensity, with modifications to the exercises.
Andere Namen:
|
|
Kein Eingriff: Control group
Participants in the Control Group will receive standard care.
They will not participate in the intervention, only answering questionnaires and performing tests during the initial assessment periods, after 4 weeks, 8 weeks, 12 weeks, and after 16 weeks.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pain assessment
Zeitfenster: From registration to the end of treatment in 16 weeks
|
Pain will be assessed using the Brief Pain Inventory (BPI), a 10-point pain intensity scale ranging from 0 (no pain) to 10 (worst imaginable pain), developed specifically for patients with cancer-related pain.
In addition, the BPI provides information on how pain interferes with daily functioning in 7 areas: general activity, walking, mood, sleep, work, enjoyment of life, and social activity.
|
From registration to the end of treatment in 16 weeks
|
|
Fatigue
Zeitfenster: From registration to the end of treatment in 16 weeks
|
Fatigue will be measured using the Piper Fatigue Scale (PFS-P).
Fatigue is a relevant symptom for cancer patients, with a greater impact than in the general population.
It is described at all stages of the cancer patient's journey, presenting as physical, emotional, or cognitive exhaustion or weakness, which can interfere with daily function and chemotherapy treatment.
|
From registration to the end of treatment in 16 weeks
|
|
General quality of life evaluation
Zeitfenster: From enrollment to end of treatment in 16 weeks
|
The instrument used to assess Quality of life will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
The questions are using a numerical scale from 0 to 100 for scales.
In the functional and global scales the EORTC-BR 30, the higher scores mean a better quality of life and lower scores mean a worse quality of life.
Unlike, in the symptom scale EORTC-BR 30, the higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From enrollment to end of treatment in 16 weeks
|
|
Quality of life specifically for breast cancer
Zeitfenster: From registration to the end of treatment in 16 weeks
|
The instrument used to assess Quality of life specifically for breast cancer will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The questions are using a numerical scale from 0 to 100 for scales.
In the functional scale the EORTC-BR 23, the higher scores mean a better quality of life and lower scores mean a worse quality of life.
Unlike, in the symptom scale the EORTC-BR 23, the higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From registration to the end of treatment in 16 weeks
|
|
Sarcopenia
Zeitfenster: From registration to the end of treatment in 16 weeks
|
Sarcopenia assessment will be performed using the SARC-F questionnaire.
The protocol includes five components: strength, assisted gait, rising from a chair, climbing stairs, and falls.
The SARC-F items were selected to reflect changes in health status associated with the consequences of sarcopenia.
SARC-F scale scores range from 0 to 10 (i.e., 0-2 points for each component; 0 = best to 10 = worst) and were dichotomized to represent symptomatic (4+) versus healthy (0-3) status.
Additionally, a modified version of the instrument, the SARC-Calf (SARC-F + CP), which integrates an anthropometric measure into the traditional score, was employed.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity of upper limbs
Zeitfenster: From registration to the end of treatment in 16 weeks
|
The Back Scratch Test is part of the battery of physical fitness tests for older adults and is used to measure the flexibility and range of motion of the shoulder joint (scapular girdle).
The test consists of placing one hand on the same shoulder and the other hand underneath, attempting to touch or overlap the middle fingers of both hands on the back.
The distance between the fingers is measured, where positive values indicate overlap and negative values indicate the distance remaining for touch.
Test scores are classified as: negative (-): If the fingers do not touch (distance between them); zero (0): If the fingers only touch; positive (+): If the fingers overlap.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity of the upper limbs
Zeitfenster: From registration to the end of treatment in 16 weeks
|
The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire is a validated self-administered instrument for assessing symptoms and functional capacity in individuals with musculoskeletal disorders of the upper limbs. The questionnaire is validated for Brazilian Portuguese and consists of 30 items that assess an individual's ability to perform certain physical activities (21 items), the severity of symptoms such as pain, tingling, and weakness (5 items), and the impact of upper limb function on social life, work, sleep, and self-confidence (4 items). Each item is scored on a scale of 1 to 5. DASH score = ({Sum of responses}/{n} - 1 ) x 25. Where n is the number of questions answered. The score ranges from 0 to 100, where the higher the value, the greater the functional disability. |
From registration to the end of treatment in 16 weeks
|
|
Quality of life specifically for breast cancer
Zeitfenster: From registration to the end of treatment in 16 weeks
|
The instrument used to assess quality of life specifically in cases of breast cancer will be the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The questions use a numerical scale from 0 to 100.
On the functional scale of the EORTC-BR-23, higher scores indicate better quality of life and lower scores indicate worse quality of life.
On the symptom scale of the EORTC-BR-23, higher scores indicate worse quality of life and lower scores indicate better quality of life.
|
From registration to the end of treatment in 16 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Functional Capacity: 6-minute walk test
Zeitfenster: From registration to the end of treatment in 16 weeks
|
Functional capacity, or cardiorespiratory fitness, will be assessed using the 6-minute walk test performed in a 10-meter corridor.
The patient will be monitored during the test for safety.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity: 6-minute step test
Zeitfenster: From registration to the end of treatment in 16 weeks
|
Functional capacity will be assessed using the 6-minute step test.
The test consists of repeatedly stepping up and down a step with a standardized height between 20 and 30 cm for a continuous period of six minutes, with the total number of cycles or steps completed being recorded at the end of the established time.
The patient will be monitored during the test for safety.
|
From registration to the end of treatment in 16 weeks
|
|
Functional independence
Zeitfenster: From registration to the end of treatment in 16 weeks
|
The Barthel Index is a widely used instrument to assess the degree of functional independence of individuals in performing basic activities of daily living.
Its score ranges from 0 to 100 points, distributed across ten dimensions that encompass tasks related to self-care and mobility.
It is a validated measure for Portuguese, with evidence of reliability and clinical applicability in different contexts of functional assessment.
|
From registration to the end of treatment in 16 weeks
|
|
General Flexibility
Zeitfenster: From registration to the end of treatment, in 16 weeks
|
For flexibility assessment, the Schober test was used, which determines functional flexibility and is more specific to the lumbar region.
It is a test with high specificity compared to the gold standard, radiography.
However, it is a quick and low-cost test, widely used in clinical practice.
The test evaluates lumbar movement restrictions through markings: on the lumbosacral joint (joining the posterior superior iliac spines) and 10 cm above; the distance between these markings is noted in an upright position.
Immediately after, the subject performs a maximum trunk flexion (lower limbs extended), and the evaluator measures the new distance between the points with a measuring tape and records the difference between the marks based on the patient's best reach score in relation to the ground.
|
From registration to the end of treatment, in 16 weeks
|
|
Upper limb strength
Zeitfenster: From registration to the end of treatment, in 16 weeks
|
Measuring handgrip strength using a dynamometer is a simple, objective, practical, and easy-to-use procedure.
Recommended by the American Society of Hand Therapists.
The instruction is to perform a maximum contraction for 3 seconds in each test.
A 30-second rest period is required between each test, and a 2-minute rest period is required between tests for each hand.
|
From registration to the end of treatment, in 16 weeks
|
|
Lower limb strength
Zeitfenster: From registration to the end of treatment, in 16 weeks
|
The 30-Second Chair Stand Test is widely used to assess lower limb strength and muscle endurance in clinical and elderly populations.
The protocol requires the participant to stand from a chair and sit down as many times as possible within 30 seconds, without using their hands.
Performance on this test is a strong predictor of functional autonomy and is directly related to screening for sarcopenia risk.
Classification varies according to age and conditioning achieved during the test, defined as: Disability Risk: >8 repetitions for women are considered predictors of high risk of falls and loss of autonomy; Cutoff Point for Sarcopenia: >15 repetitions is an indicator of reduced muscle quality.
|
From registration to the end of treatment, in 16 weeks
|
|
Muscle Mass
Zeitfenster: From registration to the end of treatment, in 16 weeks.
|
It will be measured using Bioelectrical Impedance Analysis (BIA), a widely used method that estimates muscle mass by measuring the body's resistance and reactance to the passage of a low-intensity electrical current, and is low-cost, easy to apply, and portable.
|
From registration to the end of treatment, in 16 weeks.
|
|
Self-esteem
Zeitfenster: From registration to the end of treatment in 16 weeks
|
To assess self-esteem, the Portuguese version adapted and validated by Hutz of the Rosenberg Self-Esteem Scale will be used.
The total score ranges from 10 to 40 points.
Higher scores indicate better self-esteem and lower scores indicate worse self-esteem.
|
From registration to the end of treatment in 16 weeks
|
|
Anxiety and Depression
Zeitfenster: From registration to the end of treatment, in 16 weeks.
|
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS) questionnaire.
The total score ranges from 0 to 21 points.
The cut-off points adopted will be: an anxiety score of 8 or higher; and a depression score of 9 or higher.
|
From registration to the end of treatment, in 16 weeks.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Andrea Dias Reis, Teacher, Federal University of Maranhão, São Luís, Maranhão, Brazil
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CAAE: 88530425.5.0000.5087
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Xijing HospitalAktiv, nicht rekrutierendBrustkrebs | Brustkrebs (Triple Negative Breast Cancer (TNBC))China
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
Shanghai Henlius BiotechNoch keine RekrutierungBrustkrebs (Triple Negative Breast Cancer (TNBC))China
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi SankyoRekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
Jessica Mezzanotte SharpeRekrutierungNicht-kleinzelligem Lungenkrebs | Klassisches Hodgkin-Lymphom | Plattenepithelkarzinom Mund | Melanom (Hautkrebs) | Brustkrebs (Triple Negative Breast Cancer (TNBC)) | Invasives Mammakarzinom | Nierenzellkarzinom (Nierenkrebs) | MSI-H/dMMR RektumkarzinomVereinigte Staaten